Replies to post #38835 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

NEURORX CARES ONLY ABOUT ZYESAMI APPLICATION TO COVID 19???

NeuroRx and TFF Pharmaceuticals believe the ability to deliver VIP directly to the lung via inhalation through the dry powder formulation of Zyesami could have important therapeutic implications and potentially expand the application of the drug to patients who are less severely affected by COVID-19.

https://www.drugdeliverybusiness.com/neurorx-tff-pharmaceuticals-enter-feasibility-agreement-for-zyesami-dry-powder-for-covid-19/